CN118105451A - 一种防治溃疡性结肠炎的药食同源组合物及其应用 - Google Patents
一种防治溃疡性结肠炎的药食同源组合物及其应用 Download PDFInfo
- Publication number
- CN118105451A CN118105451A CN202410119959.0A CN202410119959A CN118105451A CN 118105451 A CN118105451 A CN 118105451A CN 202410119959 A CN202410119959 A CN 202410119959A CN 118105451 A CN118105451 A CN 118105451A
- Authority
- CN
- China
- Prior art keywords
- parts
- ulcerative colitis
- edible composition
- pharmaceutical
- medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 54
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 39
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims abstract description 16
- 210000000582 semen Anatomy 0.000 claims abstract description 14
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims abstract description 11
- 208000035861 hematochezia Diseases 0.000 claims abstract description 11
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 10
- 238000004904 shortening Methods 0.000 claims abstract description 6
- 241001529821 Agastache Species 0.000 claims abstract description 5
- 241000628997 Flos Species 0.000 claims abstract description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 16
- 244000268590 Euryale ferox Species 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 244000077995 Coix lacryma jobi Species 0.000 claims description 9
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 9
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 9
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 9
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 9
- 244000270834 Myristica fragrans Species 0.000 claims description 9
- 235000009421 Myristica fragrans Nutrition 0.000 claims description 9
- 244000273928 Zingiber officinale Species 0.000 claims description 9
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 9
- 235000008397 ginger Nutrition 0.000 claims description 9
- 239000001702 nutmeg Substances 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 8
- 244000046146 Pueraria lobata Species 0.000 claims description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 8
- 244000294611 Punica granatum Species 0.000 claims description 8
- 235000014360 Punica granatum Nutrition 0.000 claims description 8
- 240000004510 Agastache rugosa Species 0.000 claims description 7
- 244000020551 Helianthus annuus Species 0.000 claims description 7
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 7
- 239000006186 oral dosage form Substances 0.000 claims description 7
- 244000197580 Poria cocos Species 0.000 claims description 5
- 235000008599 Poria cocos Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 241001162994 Rugosus Species 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 23
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 abstract description 21
- 230000000968 intestinal effect Effects 0.000 abstract description 20
- 210000001072 colon Anatomy 0.000 abstract description 9
- 230000009266 disease activity Effects 0.000 abstract description 9
- 230000004580 weight loss Effects 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract description 2
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 229920003045 dextran sodium sulfate Polymers 0.000 abstract 4
- 241000600871 Euryale <brittle star> Species 0.000 abstract 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 8
- 229960004963 mesalazine Drugs 0.000 description 8
- 230000001142 anti-diarrhea Effects 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- 208000016261 weight loss Diseases 0.000 description 7
- 230000000975 bioactive effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000010685 fatty oil Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000003871 intestinal function Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 238000011814 C57BL/6N mouse Methods 0.000 description 2
- 241000675108 Citrus tangerina Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 208000020442 loss of weight Diseases 0.000 description 2
- -1 methyl piperonyl Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- HRYLQFBHBWLLLL-UHFFFAOYSA-N (+)-costunolide Natural products C1CC(C)=CCCC(C)=CC2OC(=O)C(=C)C21 HRYLQFBHBWLLLL-UHFFFAOYSA-N 0.000 description 1
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-ZHACJKMWSA-N (e)-octadec-8-enoic acid Chemical compound CCCCCCCCC\C=C\CCCCCCC(O)=O WRIDQFICGBMAFQ-ZHACJKMWSA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HANWHVWXFQSQGJ-UHFFFAOYSA-N 1-tetradecoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCCCCCC HANWHVWXFQSQGJ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- CUGKULNFZMNVQI-UHFFFAOYSA-N Costunolid I Natural products CC1=CCC=C(/C)CCC2C(C1)OC(=O)C2=C CUGKULNFZMNVQI-UHFFFAOYSA-N 0.000 description 1
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 229930186706 Puerarin-xyloside Natural products 0.000 description 1
- 229920000241 Punicalagin Polymers 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- 229930016183 alpha-curcumene Natural products 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- HRYLQFBHBWLLLL-AHNJNIBGSA-N costunolide Chemical compound C1CC(/C)=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]21 HRYLQFBHBWLLLL-AHNJNIBGSA-N 0.000 description 1
- MMTZAJNKISZWFG-UHFFFAOYSA-N costunolide Natural products CC1CCC2C(CC(=C/C=C1)C)OC(=O)C2=C MMTZAJNKISZWFG-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 229960002511 phenobarbital sodium Drugs 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- NAAXIGQVODQJOV-PXYOAQHISA-N puerarin xyloside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C1=C(C(C(C=2C=CC(O)=CC=2)=CO1)=O)C=C1)=C1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)CO1 NAAXIGQVODQJOV-PXYOAQHISA-N 0.000 description 1
- ZJVUMAFASBFUBG-OGJBWQGYSA-N punicalagin Chemical compound C([C@H]1O[C@@H]([C@@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]2[C@@H]1OC(=O)C1=CC(O)=C(O)C(O)=C11)O)OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(OC3=O)C4=C2C(=O)OC2=C4C3=C1C(O)=C2O ZJVUMAFASBFUBG-OGJBWQGYSA-N 0.000 description 1
- LMIBIMUSUFYFJN-RSVYENFWSA-N punicalagin Natural products O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)cc5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8c(O)c(O)c(O)cc8C(=O)O[C@H]2[C@@H]9OC(=O)c%10cc(O)c(O)c(O)c%10c%11c(O)c(O)c(O)cc%11C(=O)O[C@@H]19 LMIBIMUSUFYFJN-RSVYENFWSA-N 0.000 description 1
- ZRKSVMFLACVUIU-UHFFFAOYSA-N punicalagin isomer Natural products OC1=C(O)C(=C2C3=4)OC(=O)C=4C4=C(O)C(O)=C3OC(=O)C2=C1C1=C(O)C(O)=C(O)C=C1C(=O)OC1C2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(O)OC1COC(=O)C1=CC4=C(O)C(O)=C1O ZRKSVMFLACVUIU-UHFFFAOYSA-N 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/289—Vladimiria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种防治溃疡性结肠炎的药食同源组合物及其应用,涉及中药技术领域。该组合物由葛根、芡实、茯苓、炒薏苡仁、乌梅、山药、川木香、干姜、肉豆蔻、藿香、陈皮、石榴皮、秋葵花组成,不仅能够抑制由葡聚糖硫酸钠(Dextran sulfate Sodium salt,DSS)诱导导致的溃疡性结肠炎小鼠的腹泻、体重减轻和结肠缩短,缓解便血的严重程度和降低溃疡性结肠炎小鼠的疾病活动指数得分,还能缓解由DSS诱导导致的肠道菌群紊乱。本发明能够对溃疡性结肠炎发挥确切的防治作用,采用的原料药来源广泛、成本低,且食用安全,有助于为溃疡性结肠炎的防治提供一种疗效好、价格低廉、毒性低的药品或保健品,具有显著的临床和社会意义。
Description
技术领域
本发明涉及中药技术领域,具体涉及一种防治溃疡性结肠炎的药食同源组合物及其应用。
背景技术
溃疡性结肠炎是一种慢性炎症性肠道疾病,近些年,随着生活方式变化,溃疡性结肠炎发病率和患病率逐年上升,不同城市溃疡性结肠炎发病率为千分之四点三至百分之二点二九范围,溃疡性结肠炎患病率较高,其伤残负担可达万分之二点三。
溃疡性结肠炎多发于中青年,临床表现以腹痛、频繁/持续性腹泻、体重减轻和直肠出血为主,并且因病程长、难治愈、易复发等被世界卫生组织列为国际难治性疾病和终身性疾病,极大地降低了患者的生活质量,同时也给患者及家庭带来了承重的经济和心理负担。此外,与正常人相比,溃疡性结肠炎患者患结肠癌、骨质疏松和心血管疾病的风险大大增加,给公共卫生事业带来了承重的负担。
目前,溃疡性结肠炎的主要治疗目的是缓解病情和减少炎症,避免手术切除及实现粘膜修复。因此,美沙拉嗪、5-氨基水杨酸(5-ASA)、皮质类固醇、免疫抑制剂是用于溃疡性结肠炎临床治疗的常规药物,这些药物总体而言能缓解溃疡性结肠炎患者一时的症状,但存在严重的副作用、不良反应大、停药后容易复发、长期效果不理想、耐受性差、费用高等缺点。例如,5-氨基水杨酸在溃疡性结肠炎的治疗中应用最为广泛,但常见头痛、上吐下泻、皮肤过敏反应等副反应,且对肾脏具有毒害作用。生物制剂治疗溃疡性结肠炎疗效佳,但费用昂贵。
因此,急需寻找一种防治溃疡性结肠炎的药食同源组合物及其应用解决目前溃疡性结肠炎存在严重的副作用、不良反应大、停药后容易复发、长期效果不理想、耐受性差、费用高的问题。
发明内容
针对现有技术中的上述问题,本发明提供一种防治溃疡性结肠炎的药食同源组合物及其应用,以解决现有药物副作用、不良反应大、停药后容易复发、长期效果不理想、耐受性差、费用高的问题。
本发明采用的技术方案如下:
一种用于防治溃疡性结肠炎的药食同源组合物,所述药食同源组合物的原料药为:葛根、芡实、茯苓、炒薏苡仁、乌梅、山药、川木香、干姜、肉豆蔻、藿香、陈皮、石榴皮、秋葵花。
作为优选地,所述药食同源组合物由如下原料药制成:葛根10-20重量份、芡实10-20重量份、茯苓10-20重量份、炒薏苡仁25-35重量份、乌梅10-15重量份、山药10-20重量份、川木香3-8重量份、干姜3-8重量份、肉豆蔻3-8重量份、藿香5-15重量份、陈皮10-20重量份、石榴皮5-15重量份、秋葵花5-15重量份。
作为优选地,所述药食同源组合物由如下原料药制成:葛根15重量份、芡实15重量份、茯苓15重量份、炒薏苡仁3重量份、乌梅12重量份、山药15重量份、川木香6重量份、干姜6重量份、肉豆蔻6重量份、藿香10重量份、陈皮15重量份、石榴皮10重量份;秋葵花10重量份。
作为优选地,所述的药食同源组合物为:原料药分别粉碎后再混合而成的组合物;或,原料物质混合后经粉碎得到的组合物;或,上述原料物质混合后按照常规提取方法提取后得到提取物,提取物进一步经过精致纯化工艺得到有效部位,将上述提取物、有效部位进一步按照常规制剂工艺制备得到常规口服剂型。
作为优选地,所述常规口服剂型包括片剂、胶囊剂、颗粒剂、丸剂、散剂、口服液。
作为优选地,本发明提供所述药食同源组合在制备预防和/或治疗溃疡性结肠炎的药物或保健品中的应用。
作为优选地,所述药食同源组合物在制备抑制溃疡性结肠炎腹泻的药物或保健品中的应用。
作为优选地,所述药食同源组合物在制备抑制溃疡性结肠炎便血的药物或保健品中的应用。
作为优选地,所述的药食同源组合物在制备抑制溃疡性结肠炎体重丢失的药物或保健品中的应用。
作为优选地,所述的药食同源组合物在制备抑制溃疡性结肠炎结肠缩短的药物或保健品中的应用。
本发明所提供的药食同源组合物用于制备治疗溃疡性结肠炎的制剂,所述制剂可制备成医学上可接受的任何口服剂型,包括但不限于片剂、胶囊剂、颗粒剂、丸剂、散剂、口服液、水煎剂等。
本发明药食同源组合物中各原料的药理作用:
葛根:含异黄酮成分葛根素、葛根素木糖甙、大豆黄酮、大豆黄酮甙及β-谷甾醇、花生酸,又富含多糖。具有抗炎、抗氧化、减轻肠道炎症的功效。
芡实:主要含多糖、核黄素、胡萝卜素等生物活性成分。具有止泻、抗氧化、降血糖、保护肾功能、抗血栓等多种生物活性功能。
茯苓:含有茯苓多糖、卵磷酸、胆碱、组氨酸、多种酶及锌、硒、镁、铁等物质,具有降血糖、降血脂、健脾止泻、利尿等多种生物活性功能。
炒薏苡仁:含有多糖类、薏苡仁酯、并含脂肪油,油中含肉豆蔻酸、芸苔甾醇、棕榈酸、8-十八烯酸、豆甾醇等。具有抗炎、降低血糖、健脾止泻等多种生物学活性功能。
乌梅:含有72种挥发油成分、有机酸、氨基酸及多糖。具有增进食欲、帮助消化、止泻等多种生物学活性功能。
山药:含有山药多糖、黄酮类化合物、山药碱、甾体皂苷元等成分。具有促进消化、止泻、降低血脂、调节免疫力等多种生物学活性功能。
川木香:含有挥发油,油中成分为木香内酯、木香醇、水芹烯、木香碱等。具有抗菌、抗肠炎等多种生物学活性功能。
干姜:含有挥发油,主成分为姜烯酮、α-姜黄烯、姜烯、6-姜辣醇、柠檬醛等。具有抗炎、止吐、止泻等多种生物学活性功能。
肉豆蔻:主要含脂肪油、挥发油、肉豆蔻醚等成分,脂肪油类成分主要为三肉豆蔻酸甘油酯与三油酸甘油酯,挥发油类为肉豆蔻主要活性物质,成分包括香桧烯、α-蒎烯、β-蒎烯、松油烯-4-醇、柠檬烯等。具有抗菌、抗炎、抗氧化、降血糖、止泻等多种生物学功能。
藿香:含有挥发油类、甲基胡椒酚、茴香脑、黄酮类成分等。具有抗菌、抗炎、免疫调节、止泻等多种生物活性功能。
陈皮:含有挥发油、橙皮苷、川陈皮素、黄酮、生物碱等。具有抑菌、抗氧化、抗炎、止泻、止吐等多种生物活性功能。
石榴皮:含有鞣质、没食子酸、苹果酸、以及多种生物碱、鞣花酸、咖啡酸、木犀草素和安石榴苷等多酚类化合物。具有抗病毒、抗菌、止泻等多种生物活性功能。
秋葵花:含有丰富的多糖和黄酮类化合物。具有抗氧化、抗炎等多种生物活性功能,有助于缓解肠道炎症。
综上所述,相比于现有技术,本发明具有如下优点及有益效果:
本发明提供了一种防治溃疡性结肠炎的药食同源组合物及其应用。所述的组合物是由葛根、芡实、茯苓、炒薏苡仁、乌梅、山药、川木香、干姜、肉豆蔻、藿香、陈皮、石榴皮、秋葵花组成。研究显示,葛根具有升阳止泻之功效,具有抗炎和抗氧化的作用,具有减轻肠道炎症的功效;芡实具有益气养阴、健脾胃的功效,有助于改善肠道功能;茯苓为一种利水渗湿的药物,可以对抗慢性炎症;炒薏苡仁作为一种利水渗湿、健脾胃的药物,有助于缓解肠道炎症;乌梅具有收敛止泻的作用,被认为有助于平衡肠道功能;山药有滋阴润燥、健脾胃的功效,有助于改善肠道健康;川木香作为一种舒肝理气、活血化瘀的药物,据称可以缓解肠道炎症;干姜具有温中散寒、行气止痛的作用,有助于缓解肠道不适;肉豆蔻为温中散寒、行气止痛的药物,据称可以改善肠道症状;藿香具有解表散寒、理气和胃的作用,有助于改善肠道功能;陈皮具有理气化湿、行气止痛的作用,有助于缓解肠道炎症;石榴皮具有收敛止泻、清热解毒的作用,可以减轻肠道炎症;秋葵花作为一种滋阴润燥的药物,可以改善肠道健康。本发明使用物质几乎全为药食同源物质,以调理日常饮食结构为重点,作用缓和,无明显毒副作用,可长期使用。本发明经药理研究发现,通过组合物配合能显著降低溃疡性结肠炎小鼠疾病活动指数、对结肠缩短均有不同程度缓解作用,且能显著抑制肠道菌群α多样性指数——good_coverage的降低,调节肠道菌群的组成,对溃疡性结肠炎有不同程度的防治作用;上述药食同源组合物质的来源广泛、成本低,且食用安全,本发明的应用将有助于为溃疡性结肠炎的治疗提供一种疗效好、价格低廉、毒性低的药品或保健品,具有显著的临床和社会意义。
附图说明
图1为本发明中药食同源组合干预溃疡性结肠炎小鼠,各组小鼠结肠的照片。
图2为本发明中小鼠体重变化、大便性状及便血情况进行疾病活动指数评分表。
图3为本发明药食同源组合干预溃疡性结肠炎小鼠,小鼠笼的照片。
图4为本发明中药食同源组合干预溃疡性结肠炎小鼠,各组小鼠体重变化的曲线。
图5为本发明中药食同源组合干预溃疡性结肠炎小鼠,各组小鼠结肠长度的统计图。
图6为本发明中药食同源组合干预溃疡性结肠炎小鼠,各组小鼠的疾病活动指数评分统计图。
图7为本发明中药食同源组合干预溃疡性结肠炎小鼠,各组小鼠的肠道菌群α多样性指数——good_coverage的统计图。
图8为本发明中药食同源组合干预溃疡性结肠炎小鼠,各组小鼠肠道菌群组成相对丰度的统计图。
具体实施方式
下文将结合具体实施方式和实施例,具体阐述本发明,本发明的优点和各种效果将由此更加清楚地呈现。本领域技术人员应理解,这些具体实施方式和实施例是用于说明本发明,而非限制本发明。
在整个说明书中,除非另有特别说明,本文使用的术语应理解为如本领域中通常所使用的含义。因此,除非另有定义,本文使用的所有技术和科学术语具有与本发明所属领域技术人员的一般理解相同的含义。若存在矛盾,本说明书优先。
除非另有特别说明,本发明中用到的各种原材料、试剂、仪器和设备等,均可通过市场购买得到或者可通过现有方法制备得到。
下面将结合实施例及实验数据对本申请进行详细说明。
实施例1
本实施例一种防治溃疡性结肠炎的药食同源组合物及其应用,配方:葛根、芡实、茯苓、炒薏苡仁、乌梅、山药、川木香、干姜、肉豆蔻、藿香、陈皮、石榴皮、秋葵花制备方法:按配比称取上述原料,加10倍量水煎煮2次,每次1小时,滤过并合并滤液,即得。
作为优选地,所述药食同源组合物由如下原料药制成:葛根10-20重量份、芡实10-20重量份、茯苓10-20重量份、炒薏苡仁25-35重量份、乌梅10-15重量份、山药10-20重量份、川木香3-8重量份、干姜3-8重量份、肉豆蔻3-8重量份、藿香5-15重量份、陈皮10-20重量份、石榴皮5-15重量份、秋葵花5-15重量份。
作为优选地,所述药食同源组合物由如下原料药制成:葛根15重量份、芡实15重量份、茯苓15重量份、炒薏苡仁3重量份、乌梅12重量份、山药15重量份、川木香6重量份、干姜6重量份、肉豆蔻6重量份、藿香10重量份、陈皮15重量份、石榴皮10重量份;秋葵花10重量份。
作为优选地,所述的药食同源组合物为:原料药分别粉碎后再混合而成的组合物;或,原料物质混合后经粉碎得到的组合物;或,上述原料物质混合后按照常规提取方法提取后得到提取物,提取物进一步经过精致纯化工艺得到有效部位,将上述提取物、有效部位进一步按照常规制剂工艺制备得到常规口服剂型。
作为优选地,所述常规口服剂型包括片剂、胶囊剂、颗粒剂、丸剂、散剂、口服液。
作为优选地,本发明提供所述药食同源组合物在制备预防和/或治疗溃疡性结肠炎的药物或保健品中的应用。
作为优选地,所述药食同源组合物在制备抑制溃疡性结肠炎腹泻的药物或保健品中的应用。
作为优选地,所述药食同源组合物在制备抑制溃疡性结肠炎便血的药物或保健品中的应用。
作为优选地,所述的药食同源组合物在制备抑制溃疡性结肠炎体重丢失的药物或保健品中的应用。
作为优选地,所述的药食同源组合物在制备抑制溃疡性结肠炎结肠缩短的药物或保健品中的应用。
作为优选地,所述的药食同源组合在制备调节肠道菌群紊乱的药物或保健品中的应用
采用致炎剂——DSS作为诱导剂建立溃疡性结肠炎小鼠模型,评价上述药食同源配伍对小鼠体重腹泻、便血、体重丢失等肠道炎性症状的影响。
实验药品的制备
5-氨基水杨酸(5-ASA)溶液配置:购置于上海阿拉丁生化科技股份有限公司,用生理盐水配置成终浓度为10mg/mL的混悬液,按照100mg/kg/d给药,置瓶中4℃保存备用(每2天更换一次);
DSS溶液配制:DSS购买于MP生物医疗公司(MP Biomedicals LLC),使用灭菌水配置成浓度为5%的DSS溶液,每2~3天更换一次。
实验动物
从北京维通利华实验动物技术有限公司(Beijing Vital River LaboratoryAnimal Technology Co.,Ltd.)购买重量为20±1g的雄性C57BL/6N小鼠,并饲养在四川省肿瘤医院研究所的动物房中,5~6只为一笼,每周更换2次小鼠垫料。12h/12h光照/黑夜循环,温度(22±2)℃,湿度50%~60%,自由饮食饮水。
实验过程
实验前,对小鼠进行一周的适应性喂养。其后,将40只雄性C57BL/6N小鼠随机分为5组:
Control组:生理盐水(n=8);
DSS组:生理盐水+DSS(n=8);
药食同源低剂量组(YGQFSC-L):DSS+YGQFSC(5g/kg)(n=8);
药食同源高剂量组(YGQFSC-H):DSS+YGQFSC(10g/kg)(n=8);
阳性对照组:DSS+5-ASA(n=8)。
Control组给予正常饮用水,灌胃生理盐水14d。DSS组给予生理盐水灌胃14d,第8-14d给予2.5%DSS溶液作为饮用水。DSS+YGQFSC组灌胃设置好的剂量的YGQFSC(分别为5、10g/kg)14d,同时从第8天开始至第14天饮用水更换为2.5%DSS溶液。阳性对照组给予剂量为100mg/kg的5-ASA,同时从第8天开始至第14天饮用水更换为2.5%DSS溶液。
观察指标:(1)DSS开始干预后,每天记录小鼠体重,绘制体重变化曲线;(2)DSS开始干预后,观察小鼠腹泻的情况,可以通过小鼠笼中垫料颜色的深浅以及粪便的形状;(3)DSS开始干预后,观察小鼠便血的严重程度,可通过小鼠肛门是否有血,以及出血程度;(4)DSS干预7天后,收集各组小鼠粪便,并通过16S rRNA技术检测小鼠肠道菌群的多样性和组成。
动物处理:
DSS干预7天后,腹腔注射苯巴比妥钠(120mg/kg)麻醉,迅速剖腹,将距肛门10cm长的末端结肠取出,并测量结肠的长度。
疾病活动指数评分:
观察实验动物精神状态、饮食、饮水情况,并根据小鼠体重变化、大便性状及便血情况进行疾病活动指数评分(见下图1)。
图1.疾病活动指数评分
从图2可以看出,DSS干预后小鼠的大便不成形、腹泻的严重程度增加,导致与对照组相比,小鼠笼中的垫料颜色更深、干燥度降低,但药食同源的组合物干预后,小鼠笼中的垫料更干净,包括颜色更浅和更干燥。
从图3可以看出,DSS干预后小鼠体重开始丢失,并且模型组丢失速度更快,下降的程度更低,药食同源的组合物干预后,减缓了小鼠体重丢失的速度,减小了小鼠体重丢失的幅度,并且高剂量组的干预效果优于低剂量组。
从图4和图5可以看出,与对照组相比,模型组的小鼠在DSS干预后结肠长度明显缩短,药食同源的组合物干预后,抑制了结肠的缩短。
小鼠疾病活动指数评分是基于小鼠体重下降、腹泻、便血情况进行的综合性评分,具体评分细则依照上表。从图6可以看出,模型组疾病活动指数评分获得最高,出现腹泻、肉馅可见的严重便血和体重下降明显。药食同源的组合物干预后,无论是高剂量还是低剂量组,均能降低小鼠疾病活动指数评分。
从图7可以看出,与对照组相比,模型组小鼠肠道菌群α多样性指数——good_coverage显著降低,药食同源的组合物干预后,能够显著抑制DSS诱导导致的α多样性指数——good_coverage的降低。
从图8可以看出,与对照组相比,模型组小鼠肠道菌群在门水平上的组成发生改变(拟杆菌门相对丰度降低,厚壁菌门相对丰度增加),药食同源的组合物干预后,能够抑制DSS诱导导致的小鼠肠道菌群的改变,抑制拟杆菌门相对丰度的降低和厚壁菌门相对丰度的增加。
以上实验结果表明,本发明中的药食同源组合物能够减轻腹泻、便血和体重丢失,调节肠道菌群,抑制小鼠的溃疡性结肠炎。
以上所述实施例仅表达了本申请的具体实施方式,其描述较为具体和详细,但并不能因此而理解为对本申请保护范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本申请技术方案构思的前提下,还可以做出若干变形和改进,这些都属于本申请的保护范围。
Claims (10)
1.一种用于防治溃疡性结肠炎的药食同源组合物,其特征在于,所述药食同源组合物的原料药为:葛根、芡实、茯苓、炒薏苡仁、乌梅、山药、川木香、干姜、肉豆蔻、藿香、陈皮、石榴皮、秋葵花。
2.如权利要求1所述的药食同源组合物,其特征在于,所述药食同源组合物由如下原料药制成:葛根10-20重量份、芡实10-20重量份、茯苓10-20重量份、炒薏苡仁25-35重量份、乌梅10-15重量份、山药10-20重量份、川木香3-8重量份、干姜3-8重量份、肉豆蔻3-8重量份、藿香5-15重量份、陈皮10-20重量份、石榴皮5-15重量份、秋葵花5-15重量份。
3.如权利要求2所述的药食同源组合物,其特征在于,所述药食同源组合物由如下原料药制成:葛根15重量份、芡实15重量份、茯苓15重量份、炒薏苡仁3重量份、乌梅12重量份、山药15重量份、川木香6重量份、干姜6重量份、肉豆蔻6重量份、藿香10重量份)、陈皮15重量份、石榴皮10重量份、秋葵花10重量份。
4.如权利要求1-3任一项所述的药食同源组合物,其特征在于,所述的药食同源组合物为:原料药分别粉碎后再混合而成的组合物;或,原料物质混合后经粉碎得到的组合物;或,上述原料物质混合后按照常规提取方法提取后得到提取物,提取物进一步经过精致纯化工艺得到有效部位,将上述提取物、有效部位进一步按照常规制剂工艺制备得到常规口服剂型。
5.如权利要求4所述的药食同源组合,其特征在于,所述常规口服剂型包括但不限于片剂、胶囊剂、颗粒剂、丸剂、散剂、口服液、水煎剂中的任意一种。
6.如权利要求1-3任一项所述的药食同源组合在制备预防和/或治疗溃疡性结肠炎的药物或保健品中的应用。
7.如权利要求6所述的应用,其特征在于,所述药食同源组合物在制备抑制溃疡性结肠炎腹泻的药物或保健品中的应用。
8.如权利要求6所述的应用,其特征在于,所述药食同源组合在制备抑制溃疡性结肠炎便血的药物或保健品中的应用。
9.如权利要求6所述的应用,其特征在于,所述的药食同源组合物在制备抑制溃疡性结肠炎体重丢失的药物或保健品中的应用。
10.如权利要求6所述的应用,其特征在于,所述的药食同源组合物在制备抑制溃疡性结肠炎结肠缩短的药物或保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410119959.0A CN118105451A (zh) | 2024-01-29 | 2024-01-29 | 一种防治溃疡性结肠炎的药食同源组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410119959.0A CN118105451A (zh) | 2024-01-29 | 2024-01-29 | 一种防治溃疡性结肠炎的药食同源组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118105451A true CN118105451A (zh) | 2024-05-31 |
Family
ID=91217310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410119959.0A Pending CN118105451A (zh) | 2024-01-29 | 2024-01-29 | 一种防治溃疡性结肠炎的药食同源组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118105451A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116919929A (zh) * | 2023-08-22 | 2023-10-24 | 重庆医科大学 | β-Pinene在制备治疗溃疡性结肠炎药物的应用 |
-
2024
- 2024-01-29 CN CN202410119959.0A patent/CN118105451A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116919929A (zh) * | 2023-08-22 | 2023-10-24 | 重庆医科大学 | β-Pinene在制备治疗溃疡性结肠炎药物的应用 |
CN116919929B (zh) * | 2023-08-22 | 2024-09-06 | 重庆医科大学 | β-Pinene在制备治疗溃疡性结肠炎药物的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101972338B (zh) | 一种治疗小儿上呼吸道感染的中药制剂及其制备方法 | |
CN103099959B (zh) | 一种治疗溃疡性结肠炎的中药制剂及其制备方法 | |
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN102698137A (zh) | 一种具有降低血压作用的组合物及其制备方法 | |
CN118105451A (zh) | 一种防治溃疡性结肠炎的药食同源组合物及其应用 | |
CN103405742B (zh) | 一种治疗小儿腹泻的药物组合物及其制备方法 | |
CN102579610A (zh) | 一种治疗脑出血的中药组合物及其制备方法 | |
CN106994141B (zh) | 一种治疗便秘的中药组合物及其制备方法 | |
CN103599455B (zh) | 一种用于祛斑的中药胶囊 | |
CN104524214A (zh) | 治疗消化道溃疡的中药组合物及其中药制剂、制备方法和应用 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
CN102824414A (zh) | 一种用于治疗便秘的药茶 | |
CN103041233A (zh) | 一种治疗小儿腹泻的药物组合物及其制备方法 | |
CN105535587A (zh) | 一种治疗心肾不交型心悸失眠的中药制剂及其制备方法 | |
CN105560984B (zh) | 一种益气健脾的中药组合物 | |
CN100488526C (zh) | 仙硼疗氟口服制剂 | |
CN104474103A (zh) | 一种天然植物降糖剂及其制备方法 | |
CN104922488B (zh) | 一种防治帕金森病或帕金森病运动并发症的中药组合物及其制备方法和应用 | |
CN103599288A (zh) | 一种治疗鸡传染性喉气管炎的中药口服液及其制备方法 | |
CN115252732B (zh) | 一种清肺止咳的中药组合物及其应用 | |
CN118477149B (zh) | 一种治疗咽炎的中药组合物 | |
CN102742832A (zh) | 一种保护关节的食疗产品及其制备方法 | |
CN105106533A (zh) | 一种治疗妊娠期胆结石的中药组合物 | |
CN104758842A (zh) | 一种治疗急性阑尾炎的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |